# Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer

> **NCT00898742** · — · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 58 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **GENETIC:** DNA and tissue microarray analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** mass spectrometry

## Key facts

- **NCT ID:** NCT00898742
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** study closed prematurely upon PI's departure from VICC
- **Last updated:** 2013-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00898742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00898742, "Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00898742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*